PBMC depleted of alloreactive cells by Hsp90 inhibitor display functional virus-specific responses. (A) Quantification of CMV-specific CD8⁺ T cells in PBMC and untreated or Hsp90 inhibitor-treated MLRs of a CMV-seropositive donor using a MHC class I pentamer specific for a CMV_pp65 epitope (A*0201-NLV; *numbers indicate percentages of pentamer-specific CD8⁺ cells). (B) Percentage of CMV NLV-pentamer–specific CD8⁺ cells of PBMC and untreated or 17-DMAG–treated MLRs of 3 different donors (percentage of NLV-specific CD8⁺ cells in untreated PBMC = 100%). (C) Summary of depletion efficacy in 4 experiments: quantification of supernatant IFN-γ levels after restimulation of untreated or 17-DMAG–treated MLRs of CMV-seropositive donors with the same allogeneic DC triggering the alloresponse or autologous monocytes pulsed with a CMV_pp65 peptide pool. Displayed P values were obtained using a 2-tailed paired t test.